Drugs that contain Tapentadol Hydrochloride
1. Drug name - NUCYNTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(a month ago) | |
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(2 years from now) | |
| CN1077566C | COLLEGIUM PHARM INC | Having Pharmacological Effect Of 1-Phenyl - -3 - Dimethylamino-Propane Compounds |
Jul, 2015
(7 years ago) | |
| CN1125221A | COLLEGIUM PHARM INC | Having Pharmacological Effect Of 1-Phenyl - -3 - Dimethylamino-Propane Compounds |
Jul, 2015
(7 years ago) | |
| CN1997621A | COLLEGIUM PHARM INC | Crystalline Form Of (-)-(1R, 2R)-3-(3-Dimethylamino-1-Ethide-2-Methyl Propyl)-Phenol Hydrochloride |
Jun, 2025
(2 years from now) | |
| CN1997621B | COLLEGIUM PHARM INC | (-)-(1R, 2R) -3-(3-Dimethylamino - -1 - Ethyl -2 - Methyl Propyl) - Phenol Hydrochloride Of Crystalline Form |
Jun, 2025
(2 years from now) | |
| IN242353B | COLLEGIUM PHARM INC | Crystalline Forms Of (-) -(1R, 2R) -3-(3-Dime Thylamino-1- Ethyl -2 Methyl Propyl ) -Phenol Hydrochlo Ride |
Jun, 2025
(2 years from now) | |
| IN200603453P2 | COLLEGIUM PHARM INC | Crystalline Forms Of (−)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride |
Jun, 2025
(2 years from now) | |
| EP693475B1 | COLLEGIUM PHARM INC | 1-Phenyl-3-Dimethylamino-Propane Derivatives Having Pharmacological Activity |
Jul, 2020
(2 years ago) | |
| EP693475A1 | COLLEGIUM PHARM INC | 1-Phenyl-3-Dimethylamino-Propane Derivatives Having Pharmacological Activity |
Jul, 2020
(2 years ago) | |
| EP1612203B1 | COLLEGIUM PHARM INC | Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride |
Jun, 2024
(1 year, 8 months from now) | |
| EP1612203A1 | COLLEGIUM PHARM INC | Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride |
Jun, 2024
(1 year, 8 months from now) | |
| EP1799633A2 | COLLEGIUM PHARM INC | Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions |
Jun, 2025
(2 years from now) | |
| EP1799633B1 | COLLEGIUM PHARM INC | Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions |
Jun, 2025
(2 years from now) | |
Treatment: NA
Dosage: SOLUTION;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE/ML | SOLUTION;ORAL | Discontinued |
2. Drug name - NUCYNTA ER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(a month ago) | |
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(2 years from now) | |
| CN1077566C | COLLEGIUM PHARM INC | Having Pharmacological Effect Of 1-Phenyl - -3 - Dimethylamino-Propane Compounds |
Jul, 2015
(7 years ago) | |
| CN1125221A | COLLEGIUM PHARM INC | Having Pharmacological Effect Of 1-Phenyl - -3 - Dimethylamino-Propane Compounds |
Jul, 2015
(7 years ago) | |
| CN1997621A | COLLEGIUM PHARM INC | Crystalline Form Of (-)-(1R, 2R)-3-(3-Dimethylamino-1-Ethide-2-Methyl Propyl)-Phenol Hydrochloride |
Jun, 2025
(2 years from now) | |
| CN1997621B | COLLEGIUM PHARM INC | (-)-(1R, 2R) -3-(3-Dimethylamino - -1 - Ethyl -2 - Methyl Propyl) - Phenol Hydrochloride Of Crystalline Form |
Jun, 2025
(2 years from now) | |
| IN242353B | COLLEGIUM PHARM INC | Crystalline Forms Of (-) -(1R, 2R) -3-(3-Dime Thylamino-1- Ethyl -2 Methyl Propyl ) -Phenol Hydrochlo Ride |
Jun, 2025
(2 years from now) | |
| IN200603453P2 | COLLEGIUM PHARM INC | Crystalline Forms Of (−)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride |
Jun, 2025
(2 years from now) | |
| EP693475B1 | COLLEGIUM PHARM INC | 1-Phenyl-3-Dimethylamino-Propane Derivatives Having Pharmacological Activity |
Jul, 2020
(2 years ago) | |
| EP693475A1 | COLLEGIUM PHARM INC | 1-Phenyl-3-Dimethylamino-Propane Derivatives Having Pharmacological Activity |
Jul, 2020
(2 years ago) | |
| EP1612203B1 | COLLEGIUM PHARM INC | Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride |
Jun, 2024
(1 year, 8 months from now) | |
| EP1612203A1 | COLLEGIUM PHARM INC | Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride |
Jun, 2024
(1 year, 8 months from now) | |
| EP1799633A2 | COLLEGIUM PHARM INC | Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions |
Jun, 2025
(2 years from now) | |
| EP1799633B1 | COLLEGIUM PHARM INC | Crystalline Forms Of (-)-(1R,2R)-3-(3-Dimethylamino-1-Ethyl-2-Methylpropyl)-Phenol Hydrochloride For Use As Active Ingredient In Pharmaceutical Compositions |
Jun, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11007156 | COLLEGIUM PHARM INC | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
Oct, 2022
(18 days from now) | |
| US8420056 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(1 year, 1 month from now) | |
| US8309060 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(1 year, 1 month from now) | |
| US8075872 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(1 year, 1 month from now) | |
| US8114383 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Oct, 2024
(2 years from now) | |
| US8536130 | COLLEGIUM PHARM INC | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain |
Sep, 2028
(5 years from now) | |
Treatment: Relief of moderate to severe chronic pain; management of neuropathic pain associated with diabetic peripheral neuropathy; Management of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 50MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 100MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 150MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 200MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 250MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.